Lijun Sun, PhD
Co-founder & Chair of the SABAssociate Professor & Director of Center for Drug Discovery and Translational Research Beth Israel Deaconness Medical Center, Harvard Teaching Hospital
Dr. Sun is a co-founder and Chair of the Scientific Advisory Board at Silicon Therapeutics. He is an associate professor at Harvard Medical School and the Director of Center for Drug Discovery and Translational Research at the Department of Surgery, Beth Israel Deaconess Medical Center. Previously, Dr. Sun held executive positions in a number of emerging biotech companies where he led anticancer and antiinflammation drug discovery and development programs. His most recent positions include Vice President of Chemistry and Pharmaceutical Science at Theracrine, Inc., a Flagship Venture startup that focused on the discovery of antimetastatic anticancer therapeutics. Prior to this, he was the Vice President of Chemistry at Synta Pharmaceuticals, where he was instrumental in building the Company’s entire program portfolio including the first-in-class anticancer NCEs elesclomol (Phase-3), ganetespib (Phase-3), and apilomod (Phase-2), as well as the immune modulator Ro-2959 (pre-IND). He also played leadership roles in scientific due diligence that led to $1+ billion deals with GSK and Roche, respectively.
Dr. Sun is a co-inventor of >100 issued or pending US patents covering novel chemical entities, manufacturing processes, formulations, and physical forms. He has authored >30 peer-reviewed publications in virtual screening, structure-based drug designs, and chemical biology. He received his Ph.D. degree in organic chemistry from Emory University and trained as a postdoctoral research fellow in biomedical research at Emory Medical School
Dr. Finith Jernigan, III, PhD
Dr. Jernigan is a co-founder of Silicon Therapeutics and was instrumental in developing the underlying technology INSITE. Prior to founding Silicon Therapeutics, Dr. Jernigan was at Beth Israel Deaconess Medical Center, a teaching hospital of Harvard Medical School, where his focused on identification of tool compounds using novel in silico screening approaches for targets identified by BIDMC investigators. This work, performed in the labs of Drs. Sun and Chaikof, led to the creation Silicon Therapeutics’ proprietary drug discovery platform, INSITE. Prior to that, Dr. Jernigan earned his Ph.D. in organic chemistry at the University of North Carolina at Chapel Hill in the lab of Dr. David S. Lawrence. His work at the University of North Carolina focused on the synthesis and development of fluorescent sensors of kinases and the proteasome. This work led to multiple publications in top chemistry journals, including Journal of the American Chemical Society and Angewandte Chemie International Edition. Dr. Jernigan holds a B.S. in Biochemistry from Salisbury University, a Ph.D. in Organic Chemistry from the University of North Carolina at Chapel Hill, and was a postdoctoral fellow at BIDMC/Harvard Medical School.
Co-founder & CEOVenture Partner, Chengwei Capital
Lanny co-founded Silicon Therapeutics and handles the firms day to day operations as well as partnership and financing initiatives. He has spent his entire career in the healthcare sector working across a number of industries including drug discovery, CRO, investment banking, consulting, venture capital, private equity and non-profits. He started his career on Wall Street with Deutsche Bank Securities where he focused on Healthcare M&A and financings, completing over USD3.0bn worth of M&A and financing transactions. He then went on to assist multiple US teaching hospitals and private equity firms in their China market entry strategy as relating to healthcare, advising on over USD300mm in cross border transactions and developments including an USD250 million aged care community in Shanghai and a USD50 million cross border medical technologies fund. He joined Chengwei in 2015 to help the firm drive its healthcare portfolio strategy, including computational drug discovery and biotechnologies. He received his Bachelors of Science in Economics from Trinity College in Hartford, CT.
Woody Sherman, PhD
Dr. Sherman joins Silicon from Schrödinger, a leader in computational chemistry software development, where he was vice president and global head of the Applications Science team, helping pharmaceutical companies apply computational chemistry tools to challenging targets. He was also part of the senior management team and was involved in modeling services, methods development, and product management. Dr. Sherman is a leader in molecular simulations and computer-aided drug design, with over 70 publications covering novel methods and applications. He completed his Ph.D. at MIT with Professor Bruce Tidor, PhD, where he examined the role of electrostatics and dynamics in protein-ligand binding, and developed a novel method for optimizing ligand binding specificity across a panel of (desirable and undesirable) targets. Dr. Sherman has published on a broad range of topics, including free energy simulations, molecular dynamics, induced-fit docking, virtual screening, lead optimization, selectivity design, cheminformatics, and protein design.He is on the Editorial Board of Chemical Biology & Drug Design and the Journal of Chemical Information and Modeling.
Dr. Jingsong Wang, MD, PhD
Director of the BoardCEO, Harbour BioMed
Dr. Jingsong Wang is the CEO of Harbour BioMed (HBM). Before founding HBM, he was the Head of China Research and Development and of Translational Medicine, Asia Pacific, for Sanofi. Dr. Wang joined Sanofi from Bristol-Myers Squibb, where he served in multiple roles with increasing responsibilities, including Director of Discovery Medicine and Clinical Pharmacology and Global Program Lead for multiple pre-clinical and clinical assets. Dr. Wang completed his Clinical Rheumatology Fellowship and subsequently was an Attending Rheumatologist and faculty member at Brigham and Women's Hospital and Harvard Medical School. Dr. Wang received his PhD in Molecular Pharmacology from China Pharmaceutical University and has also completed a Molecular Immunology Research Fellowship at Dr. Laurie Glimcher’s laboratory at the Harvard School of Public Health. Dr. Wang is an Adjunct Assistant Professor of Medicine at the University of Pennsylvania. He has served on the Research Grant Review Committee, National Natural Science Foundation of China, and as a scientific grant reviewer for the Medical Research Council, National Institute for Health Research, National Health Service of the United Kingdom.